KAHR Medical Israeli Company

KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity.